RETINITIS PIGMENTOSA
Clinical trials for RETINITIS PIGMENTOSA explained in plain language.
Never miss a new study
Get alerted when new RETINITIS PIGMENTOSA trials appear
Sign up with your email to follow new studies for RETINITIS PIGMENTOSA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to slow vision loss in rare usher syndrome
Disease control CompletedThis study tests whether NPI-001 tablets can safely slow or stop vision loss in people with Usher syndrome, a rare genetic condition that causes blindness and hearing loss. About 49 adults will take either the study drug or a placebo for 24 months. The main goal is to see if the …
Matched conditions: RETINITIS PIGMENTOSA
Phase: PHASE1, PHASE2 • Sponsor: Nacuity Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
Gene therapy shows promise for rare Blindness-Causing eye disease
Disease control CompletedThis early-stage study tested a gene therapy called CPK850 in 12 adults with a rare inherited eye disease (RLBP1 retinitis pigmentosa) that causes progressive vision loss and night blindness. The treatment was injected under the retina to deliver a working copy of the faulty gene…
Matched conditions: RETINITIS PIGMENTOSA
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental eye injection aims to restore sight in rare blindness conditions
Disease control CompletedThis study tested an experimental drug called KIO-301, given as an injection into the eye, in 32 adults with retinitis pigmentosa or choroideremia—two inherited conditions that cause progressive vision loss. The main goal was to check safety and tolerability at increasing doses. …
Matched conditions: RETINITIS PIGMENTOSA
Phase: PHASE1, PHASE2 • Sponsor: Kiora Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental eye drug targets genetic blindness
Disease control CompletedThis phase II trial tested an experimental drug called ADX-2191 in 8 adults with retinitis pigmentosa caused by specific genetic mutations. Participants received monthly injections into one eye for up to six months. The main goal was to check safety, but researchers also looked a…
Matched conditions: RETINITIS PIGMENTOSA
Phase: PHASE2 • Sponsor: Aldeyra Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Massive DNA bank launched to unlock secrets of rare eye diseases
Knowledge-focused CompletedThis study created a national DNA and blood repository for inherited eye diseases like retinitis pigmentosa. Over 6,600 participants provided blood samples and eye exam data to help researchers identify genetic causes. The stored samples are available to scientists without person…
Matched conditions: RETINITIS PIGMENTOSA
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Eye tests under the microscope for blinding disease
Knowledge-focused CompletedThis completed study looked at how well different eye tests can track changes in retinitis pigmentosa (RP), a group of blinding eye diseases. Researchers tested 49 people with RP and healthy volunteers using exams like vision tests, retinal imaging, and electrical signal recordin…
Matched conditions: RETINITIS PIGMENTOSA
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC